Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$9.50|
|52 Week High||US$9.39|
|52 Week Low||US$23.49|
|1 Month Change||-26.13%|
|3 Month Change||-16.23%|
|1 Year Change||-51.78%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-56.82%|
Recent News & Updates
Here's Why We're Not Too Worried About Akouos' (NASDAQ:AKUS) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Akouos names Kathy Reape as chief development officer
Akouos (AKUS) announces the appointment of Kathy Reape as the company's chief development officer. Reape brings over 20 years of experience in the pharmaceutical industry, including gene therapy translational and development expertise.Prior to joining Akouos, he was most recently Chief Medical Officer at Spark Therapeutics.
|AKUS||US Biotechs||US Market|
Return vs Industry: AKUS underperformed the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: AKUS underperformed the US Market which returned 30.3% over the past year.
Stable Share Price: AKUS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: AKUS's weekly volatility (8%) has been stable over the past year.
About the Company
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company’s precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene.
Akouos Fundamentals Summary
|AKUS fundamental statistics|
Is AKUS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AKUS income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.87|
|Net Profit Margin||0.00%|
How did AKUS perform over the long term?See historical performance and comparison
Is Akouos undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AKUS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AKUS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AKUS is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: AKUS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AKUS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AKUS is good value based on its PB Ratio (1.2x) compared to the US Biotechs industry average (2.9x).
How is Akouos forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AKUS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AKUS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AKUS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AKUS is forecast to have no revenue next year.
High Growth Revenue: AKUS is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AKUS's Return on Equity is forecast to be high in 3 years time
How has Akouos performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: AKUS is currently unprofitable.
Growing Profit Margin: AKUS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if AKUS's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare AKUS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AKUS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: AKUS has a negative Return on Equity (-23.31%), as it is currently unprofitable.
How is Akouos's financial position?
Financial Position Analysis
Short Term Liabilities: AKUS's short term assets ($274.0M) exceed its short term liabilities ($12.1M).
Long Term Liabilities: AKUS's short term assets ($274.0M) exceed its long term liabilities ($28.0M).
Debt to Equity History and Analysis
Debt Level: AKUS is debt free.
Reducing Debt: AKUS had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AKUS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: AKUS has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 56.7% each year
What is Akouos's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AKUS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AKUS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AKUS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AKUS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AKUS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Manny Simons (38 yo)
Dr. Emmanuel Simons, Ph D., M.B.A., also known as Manny, Co-founded Akouos in March 2016 and has been its President and Chief Executive Officer and Director since March 2016. Dr. Simons served as Principal...
CEO Compensation Analysis
Compensation vs Market: Manny's total compensation ($USD7.18M) is above average for companies of similar size in the US market ($USD1.68M).
Compensation vs Earnings: Manny's compensation has increased whilst the company is unprofitable.
Experienced Management: AKUS's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: AKUS's board of directors are considered experienced (3.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Akouos, Inc.'s employee growth, exchange listings and data sources
- Name: Akouos, Inc.
- Ticker: AKUS
- Exchange: NasdaqGS
- Founded: 2016
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$327.562m
- Shares outstanding: 34.48m
- Website: https://www.akouos.com
Number of Employees
- Akouos, Inc.
- 645 Summer Street
- Suite 200
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/24 22:03|
|End of Day Share Price||2021/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.